| Document |
Document Title |
|
WO/2023/125704A1 |
The present invention relates to a method for preparing an activated expanded lymphocyte stock solution, the preparation method comprising the following steps: (1) In a serum-free medium, co-culturing a lymphocyte activator with peripher...
|
|
WO/2023/127883A1 |
The present invention provides a compound indicated by general formula (1) and having mPGES-1 inhibitory activity, a pharmaceutically acceptable salt thereof, or a solvate thereof (in the formula, R1 and R2 each independently indicate hy...
|
|
WO/2023/123215A1 |
Provided are the uses of extracellular vesicles. Further specifically provided are the uses of extracellular vesicles in the aspects of adjusting the ovarian function, prolonging the life of mammals or preventing aging, treating or preve...
|
|
WO/2023/118092A1 |
The present invention relates to substituted pyrazolo[l,5-a]pyridine-[3,2-e]pyrimidines compounds of formula (I) wherein X, R1, and R2 are as defined in the claims, methods of preparing said compounds, pharmaceutical compositions and com...
|
|
WO/2023/118729A1 |
The present invention relates to a Limosilactobacillus fermentum strain chosen from the strain deposited with the CNCM on 17 November 2021 under number I-5777 or under number I-5778, for use thereof in the prevention and/or treatment of ...
|
|
WO/2023/119333A1 |
The present application relates to a process for preparation of relugolix or its pharmaceutically acceptable salts thereof. The present application also relates to the process for preparation of Relugolix crystalline form R1.
|
|
WO/2023/122075A1 |
Disclosed herein are compositions comprising sterol-amino-phosphate compounds and methods of making and use thereof. Also disclosed herein are methods of making and methods of use of the compounds, compositions, and/or lipid particles di...
|
|
WO/2023/109784A1 |
The present invention relates to the technical field of biomedicines, and in particular, to a use of an SGLT2 inhibitor in preparation of a drug for preventing and treating male reproductive dysfunction. Research results of the present i...
|
|
WO/2023/109783A1 |
The present invention relates to the technical field of biomedicines. In particular, the present invention relates to a use of canagliflozin and analogs thereof in preparation of a drug for preventing and treating male reproductive dysfu...
|
|
WO/2023/098158A1 |
The present invention relates to the technical field of medicines. Disclosed is a needle-medicine integrated hydrogel microneedle. A microneedle matrix is hydrogel formed by a gelatin and tannic acid cross-linked product, a medicine is e...
|
|
WO/2023/100925A1 |
Provided is an asymmetric cell division inhibitor with which infertility due to aging or the like can be ameliorated. The asymmetric cell division inhibitor includes a spontaneous activation inhibitor that inhibits asymmetric cell divi...
|
|
WO/2023/101157A1 |
The present invention relates to a composition for preventing, treating or ameliorating a bone disease or a menopausal disease, comprising, as an active ingredient, a Salicornia europaea hot water extract obtained by subjecting Salicorni...
|
|
WO/2023/100184A1 |
Provided a composition or a kit based on triptolide, gossypol and acceptable salts thereof. The current composition or kit based on triptolide, gossypol and acceptable salts thereof can be used for limiting or inhibiting birth rate inclu...
|
|
WO/2023/095802A1 |
The present disclosure provides a pharmaceutical composition for treating or preventing T cell-related disorders, the pharmaceutical composition containing induced regulatory T cells having high functionality and a stable immunosuppressi...
|
|
WO/2023/092150A1 |
Described herein are methods and compositions for using microbial agents (probiotics) and agents that promote growth of certain microbes (prebiotics) for management (including prevention and treatment) of musculoskeletal disorders, inclu...
|
|
WO/2023/090552A1 |
The present invention relates to a novel Lactobacillus plantarum stain. In addition, the present invention relates to a composition for preventing, ameliorating or treating infertility, containing a Lactobacillus plantarum strain. The La...
|
|
WO/2023/088287A1 |
The compositions of a glycosylated and/or sialylated core peptide (073 core) and compositions of proteins based on fusion of one or more copy of the peptide to the Fc fragment of human immunoglobulin and their use in treating diseases pr...
|
|
WO/2023/091684A1 |
Described herein are crystalline composition, methods of making such crystalline composition, pharmaceutical compositions and medicaments comprising such crystalline composition, and methods of using such crystalline composition in the t...
|
|
WO/2023/089338A1 |
The present invention provides a clostridial neurotoxin for use in a method of suppressing visceral pain in a patient. The method comprises: (a) identifying an organ in the patient that is causing said visceral pain; (b) mapping said org...
|
|
WO/2023/091390A1 |
Provided herein are methods and compositions for asparagus racemosus and withania somnifera in treating the quality of life, improving endothelial function and biomarkers, bone health biomarkers, and bone mineral density (BMD) in postmen...
|
|
WO/2023/088351A1 |
Provided is the use of a nerve growth factor in the preparation of a drug for treating or improving diseases of the reproductive system.
|
|
WO/2023/083195A1 |
Provided in the present invention are the preparation for a chimeric antigen receptor immune cell constructed on the basis of a growth arrest-specific protein 6 and the use of the chimeric antigen receptor immune cell. Specifically, prov...
|
|
WO/2023/083979A1 |
The present disclosure concerns the novel compounds 3α-ethyl-3β-hydroxy-5α-androstan-17-one and 3α-ethyl-3β-hydroxy-5α-androstan-17-one, the medical use thereof and in particular use in the treatment of diseases and disorders assoc...
|
|
WO/2023/083815A1 |
The invention relates to a KISS1R receptor agonist peptide compound chosen from the compounds of formula (I) and analogues thereof capable of binding the KISS1R receptor, or a salt thereof: R1-Xaa1-Xaa2-Xaa3-Asn-Xaa4-Phe-Xaa5-Xaa6-Xaa7-X...
|
|
WO/2023/083980A1 |
The present disclosure concerns the use of 3α-ethynyl-3β-hydroxy-5α-androstan-17-one as medicament, in particular in treatment of a disease or disorder associated with an α3 subtype of the GABAA receptor. The present disclosure is sp...
|
|
WO/2023/082007A1 |
The disclosure relates to methods, products and compositions useful for the derivation of naïve bovine embryonic stem cells. ECM-coated substrates comprising a positively charged biocompatible polymer are described that allow for embryo...
|
|
WO/2023/083978A1 |
The present disclosure concerns the novel compound 3. alpha.- ethynyl-3. beta.-hydroxy-5. alpha.-androstan-17-methoxime, the medical use thereof and in particular use in the treatment of diseases and disorders associated with an a3 subty...
|
|
WO/2023/080764A1 |
The present invention provides the lactic acid bacterium strain L. salivarius CLS0420 (KCTC 13815BP) or L. paracasei CLPC0629 (KCTC 14726BP). In addition, the present invention provides a use of the strain for the prevention or treatment...
|
|
WO/2023/078073A1 |
An oral preparation containing a progestogen, and a preparation method and the use. The oral preparation does not contain or contains only benzyl benzoate in a weight percentage of less than 8%. The preparation contains 17-α hydroxyprog...
|
|
WO/2023/072772A1 |
A composition for use in treating and/or preventing menstrual symptoms wherein the composition comprises (i) fennel and chamomile or (ii) fennel, ginger and lemon balm.
|
|
WO/2023/075357A1 |
The present invention relates to a novel Lactobacillus sp. strain, a culture thereof, and a composition for treating vaginitis, comprising same and, in particular, to a novel Lactobacillus crispatus strain isolated from the vagina of a h...
|
|
WO/2023/072872A1 |
The present invention relates to a tadalafil oral suspension comprising 0.01-5 % w/v of tadalafil, a cyclodextrin, coprocessed microcrystalline cellulose and sodium carboxymethyl cellulose, xanthan gum and water as vehicle. The suspensio...
|
|
WO/2023/076937A1 |
A method for treating a noncancerous gynecological disorder comprising: administering to a patient and effective amount of composition comprising a cannabis extract comprising cannabidiol (CBD), wherein the composition is preferably admi...
|
|
WO/2023/070892A1 |
A preparation method for a novel veterinary uterine infusion, belonging to the field of veterinary drug preparation. The preparation method comprises: separately mixing an adsorption carrier with a rifaximin self-microemulsion and a grow...
|
|
WO/2023/076931A2 |
A method for producing full spectrum hemp extract comprising extracting substances from cannabis-based green material that are soluble in an extraction solvent and collecting an extract that includes the extraction solvent distilling at ...
|
|
WO/2023/072284A1 |
The present invention relates to a class of gonadotropin-releasing hormone antagonists, which have antagonistic activity to gonadotropin-releasing hormone and can be used for preventing or treating sex hormone-dependent diseases, such as...
|
|
WO/2023/070102A1 |
A feminine hygiene system contains one or more feminine hygiene products that establish, restore, or maintain an optimal vaginal microbiome, an optimal interior environment of the vagina, and healthy vaginal tissue, including ion concent...
|
|
WO/2023/066941A1 |
This disclosure relates to crystalline solvated forms of N-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-diox
o-1,2,3,4-tetrahydrothieno[2,3- d]pyrimidin-6-yl)phenyl)-N'-methoxyurea. It also relate...
|
|
WO/2023/068778A1 |
The present invention relates to a composition for the prevention and treatment of female menopausal diseases, comprising phytogen as an active ingredient, and may contribute to the prevention and treatment of female menopausal diseases ...
|
|
WO/2023/069507A1 |
A method for treating a subject having, or at risk of having, damaged endometrial tissue generally includes administering to the subject an amount of a PEP preparation effective to treat the subject's endometrial tissue. The PEP preparat...
|
|
WO/2023/068366A1 |
The present invention addresses mainly the problem of providing a novel composition or pharmaceutical that targets the mitochondrial network etc. and exhibits excellent anticancer activity while having a minimal effect on normal cells....
|
|
WO/2023/066923A1 |
The present invention, generally speaking, relates to methods of contraception in male subjects, which may be a human or a non-human mammal. The present inventors have surprisingly found that the zona pellucida (ZP) proteins, especially ...
|
|
WO/2023/060310A1 |
There is provided a sperm extender medium for prolonging the fertility of bovine spermatozoa during liquid storage of the spermatozoa. The medium comprises a monosaccharide energy source for the spermatozoa. The one or more α or β amin...
|
|
WO/2023/062641A1 |
The present disclosure provides combinations inhibitors of phosphatidylinositol 3 -kinase (PI3K) pathway and agonists of anti-Mullerian hormone receptor type 2 (AMHR2), compositions and kits comprising the same, methods and uses thereof ...
|
|
WO/2023/061468A1 |
Provided are a new crystal form and use of a nitrogenous tricyclic compound in the field of drugs. Specifically, the present invention relates to a new crystal form of 2-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole-4-yl)metho
xy)-10H-...
|
|
WO/2023/061473A1 |
Disclosed is a new crystal form of compound 2-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole-4-yl)metho
xy)-10H-spiro[benzo[6],7]oxazepine[3,2-b]pyridine-11,1'-cycl
opropane]-7-formic acid. The new crystal form is crystal form J. Furthe...
|
|
WO/2023/063242A1 |
One purpose of the present invention is to provide an autoimmune disease therapeutic agent that can selectively inhibit IFN-γ, does not have a risk of biological contamination, and can be stored at room temperature. Provided is an autoi...
|
|
WO/2023/059728A1 |
The present invention concerns methods of treating and/or preventing sexual dysfunction, wherein the sexual dysfunction is associated with one or more mental health conditions, the method using a pharmaceutical composition comprising the...
|
|
WO/2023/057626A1 |
Novel oral and stable pharmaceutical compositions comprising progesterone or a pharmaceutically acceptable salt thereof in combination with estradiol or a pharmaceutically acceptable salt thereof are provided. The present invention provi...
|
|
WO/2023/051412A1 |
A β-NGF fusion protein, and a preparation method therefor and the use thereof. Specifically, the present invention relates to a β-NGF fusion protein, which contains: (a) a light chain containing β-NGF; and (b) a heavy chain containing...
|
